TCT18: CorFlow Presents Scientific Findings and is Selected as Finalist in the TCT Shark Tank Innovation Competitionadmin
CorFlow Presents Scientific Findings and is Selected as Finalist in the TCT Shark Tank Innovation Competition
Baar, Switzerland, September 18th 2018
CorFlow Therapeutics AG today announced that the company has been selected to present the CorFlow Controlled Flow Infusion (CoFI™) technology during the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego, September 21st – 25th 2018.
Among a group of more than 30 disruptive catheter based technologies, CorFlow has been selected as a finalist and will present during the TCT Shark Tank Innovation Competition. The company will present the CoFI™ technology during three different sessions:
Saturday 22nd 8:00 – 11:00 AM TCT Shark Tank Competition, Ballroom 6A, Upper Level
9:50 AM “Controlled Flow Infusion: A New Approach to Measure Dynamic Microvascular Resistance and to Treat Microvascular Obstruction in Acute Heart Attack Patients in the Cath Lab: CorFlowTherapeutics AG”, presented by Jon H. Hoem, CEO & co-Founder, CorFlow Therapeutics AG, Baar, Switzerland
12:45 – 1:45 PM Vulnerable Plaques and Vulnerable Patients, Moderated Posters 2, Exhibit Hall, Ground Level
1:09-1:16 TC 282 “Unstable Coronary Microvascular Physiology The Critical Relationship of Patency and Perfusion Pressure Assessed By Controlled Flow Infusion”, presented by Dr. Robert S. Schwartz, interventional cardiologist & CorFlow co-Founder, Minneapolis Heart Institute, Minneapolis, MN, USA
Monday 24th 11:30 – 12:30 Coronary Physiology in AMI Patients, Moderated Posters 7, Exhibit Hall, Ground Level
12:18 PM TCT 874 “Coronary Microvascular Function During STEMI: Real Time Absolute Dynamic Microvascular Resistance in An Experimental Porcine Model Using Controlled Flow Infusion”, presented by Dr. Robert S. Schwartz, interventional cardiologist & CorFlow co-Founder, Minneapolis Heart Institute, Minneapolis, MN, USA
CorFlow looks forward to present the latest scientific findings at the TCT conference which is one of the leading conferences to discuss breakthrough advances in interventional cardiology.
CorFlow has since its foundation in June 2016 worked to document that the CoFI™ technology is able to measure the coronary microvascular status. The technology uses several proprietary and innovative technologies including the OptoWire™, Opsens (TSXV:OPS) (OTCQX:OPSSF)’ 2nd generation Fiber Optic pressure guidewire. The OptoWire™ has been designed to provide the lowest drift in the industry and excellent lesions access. The CorFlow techn-ology provides a diagnostic tool and a therapeutic approach to the compromised coronary microcirculation in the cathlab fitting the workflow for acute heart attack (STEMI) patients. Microvascular obstruction (MVO) is proven to be an independent marker for adverse outcomes in these patients including death and heart failure.
The TCT Conference
The Transcatheter Cardiovascular Therapeutics (TCT) conference is one of the world’s largest and most important educational meeting specialising in interventional cardiovascular medicine. For 30 years, TCT has been the centre of cutting-edge educational content, showcasing the latest advances in current therapies and clinical research. TCT is the annual scientific symposium of the Cardiovascular Research Foundation.
TCT is designed for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine.
CorFlow Therapeutics is honoured to present the recent scientific findings using the CoFI™ technology during the TCT 30th anniversary conference in San Diego, CA, USA, Sept. 21-25.
The company has filed the dossier for the First-in-Man clinical trial named the MOCA I (Microvascular Obstruction with the CoFI™ System Assessment) trial. The MOCA I trial will investigate the safety and feasibility of the diagnostic and therapeutic components of the CoFI™ technology. In total 40 acute heart attack (STEMI) patients will be investigated at six prominent cardiovascular centres in Switzerland, Belgium, the UK and Germany.
We look forward to see you in San Diego!